MX377157B - Preparación para usarse en el tratamiento de un cáncer positivo de gd2. - Google Patents
Preparación para usarse en el tratamiento de un cáncer positivo de gd2.Info
- Publication number
- MX377157B MX377157B MX2014013858A MX2014013858A MX377157B MX 377157 B MX377157 B MX 377157B MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 377157 B MX377157 B MX 377157B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- positive cancer
- treatment
- antibody
- administering
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/061618 WO2013189516A1 (en) | 2012-06-18 | 2012-06-18 | Method for treating a gd2 positive cancer |
| PCT/EP2012/064970 WO2013189554A1 (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013858A MX2014013858A (es) | 2015-02-12 |
| MX377157B true MX377157B (es) | 2025-03-07 |
Family
ID=46317406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013858A MX377157B (es) | 2012-06-18 | 2012-07-31 | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10294305B2 (enExample) |
| JP (1) | JP6283665B2 (enExample) |
| KR (1) | KR101927118B1 (enExample) |
| CN (1) | CN104487088A (enExample) |
| AP (1) | AP2014008129A0 (enExample) |
| AU (1) | AU2012383254B2 (enExample) |
| BR (1) | BR112014031806A8 (enExample) |
| CA (1) | CA2876529C (enExample) |
| EA (1) | EA038188B1 (enExample) |
| HK (1) | HK1203375A1 (enExample) |
| IL (1) | IL235696A0 (enExample) |
| MX (1) | MX377157B (enExample) |
| SG (2) | SG11201408487WA (enExample) |
| WO (2) | WO2013189516A1 (enExample) |
| ZA (1) | ZA201407961B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| ES2768649T3 (es) | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| DK3154583T3 (da) * | 2014-06-04 | 2021-03-22 | Biontech Res And Development Inc | Humane monoklonale antistoffer mod gangliosid gd2 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| CA3076482A1 (en) * | 2017-09-21 | 2019-03-28 | Umc Utrecht Holding B.V. | Anti-gd2 antibody for the treatment of neuroblastoma |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| WO2020165402A1 (en) | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| ES3031393T3 (en) * | 2019-08-01 | 2025-07-08 | Univ Mie | Gd2 binding molecule |
| EP4093429A4 (en) * | 2019-11-26 | 2024-05-22 | University of Utah Research Foundation | COMPOSITIONS AND METHODS FOR REGULATION OF HLA CLASS I ON TUMOR CELLS |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| JP2023532753A (ja) | 2020-07-06 | 2023-07-31 | イーユーエスエー ファーマ （ユーケー） リミテッド | Ｇｄ２陽性がんを治療するための方法 |
| EP4116330A1 (en) * | 2021-07-05 | 2023-01-11 | Trion Research GmbH | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| JP2024524527A (ja) * | 2021-07-05 | 2024-07-05 | トリオン リサーチ ゲーエムベーハー | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
| EP4194471A1 (en) * | 2021-12-10 | 2023-06-14 | Y-Mabs Therapeutics, Inc. | Anti-gd2 administration regimen |
| GB202307103D0 (en) | 2023-05-12 | 2023-06-28 | Prinses Maxima Centrum Voor Kinderoncologie B V | Method for detecting a GD2 positive cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| EP2325205A3 (en) * | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| PT1572748E (pt) * | 2002-12-17 | 2010-09-28 | Merck Patent Gmbh | Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2 |
| WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| CN101292036B (zh) | 2005-10-21 | 2016-04-13 | 弗·哈夫曼-拉罗切有限公司 | 用于重组表达多肽的方法 |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| TWI466684B (zh) | 2008-06-30 | 2015-01-01 | Morphotek Inc | 抗ｇｄ２抗體及其相關方法及用途 |
| NZ603581A (en) * | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| ES2768649T3 (es) | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
-
2012
- 2012-06-18 WO PCT/EP2012/061618 patent/WO2013189516A1/en not_active Ceased
- 2012-07-31 MX MX2014013858A patent/MX377157B/es active IP Right Grant
- 2012-07-31 KR KR1020147033790A patent/KR101927118B1/ko active Active
- 2012-07-31 JP JP2015517621A patent/JP6283665B2/ja active Active
- 2012-07-31 AU AU2012383254A patent/AU2012383254B2/en active Active
- 2012-07-31 HK HK15103941.7A patent/HK1203375A1/xx unknown
- 2012-07-31 EA EA201500019A patent/EA038188B1/ru unknown
- 2012-07-31 CN CN201280074061.1A patent/CN104487088A/zh active Pending
- 2012-07-31 SG SG11201408487WA patent/SG11201408487WA/en unknown
- 2012-07-31 CA CA2876529A patent/CA2876529C/en active Active
- 2012-07-31 AP AP2014008129A patent/AP2014008129A0/xx unknown
- 2012-07-31 BR BR112014031806A patent/BR112014031806A8/pt not_active Application Discontinuation
- 2012-07-31 SG SG10201610532QA patent/SG10201610532QA/en unknown
- 2012-07-31 WO PCT/EP2012/064970 patent/WO2013189554A1/en not_active Ceased
-
2014
- 2014-02-18 US US14/182,776 patent/US10294305B2/en active Active
- 2014-10-31 ZA ZA2014/07961A patent/ZA201407961B/en unknown
- 2014-11-13 IL IL235696A patent/IL235696A0/en unknown
-
2017
- 2017-09-11 US US15/700,538 patent/US11447565B2/en active Active
-
2019
- 2019-04-04 US US16/375,022 patent/US20200055953A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/933,295 patent/US20230340148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA038188B1 (ru) | 2021-07-21 |
| CN104487088A (zh) | 2015-04-01 |
| AU2012383254A1 (en) | 2014-11-20 |
| KR20150030650A (ko) | 2015-03-20 |
| AP2014008129A0 (en) | 2014-12-31 |
| US20180134801A1 (en) | 2018-05-17 |
| WO2013189516A1 (en) | 2013-12-27 |
| BR112014031806A8 (pt) | 2018-01-16 |
| US20200055953A1 (en) | 2020-02-20 |
| BR112014031806A2 (pt) | 2017-08-29 |
| JP2015521607A (ja) | 2015-07-30 |
| JP6283665B2 (ja) | 2018-02-21 |
| CA2876529A1 (en) | 2013-12-27 |
| ZA201407961B (en) | 2015-10-28 |
| AU2012383254B2 (en) | 2017-12-14 |
| US11447565B2 (en) | 2022-09-20 |
| KR101927118B1 (ko) | 2019-03-12 |
| WO2013189554A1 (en) | 2013-12-27 |
| EA201500019A1 (ru) | 2015-05-29 |
| SG11201408487WA (en) | 2015-02-27 |
| HK1203375A1 (en) | 2015-10-30 |
| US20230340148A1 (en) | 2023-10-26 |
| CA2876529C (en) | 2023-09-26 |
| US10294305B2 (en) | 2019-05-21 |
| IL235696A0 (en) | 2015-01-29 |
| SG10201610532QA (en) | 2017-02-27 |
| US20140170155A1 (en) | 2014-06-19 |
| MX2014013858A (es) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| BR112013006673A2 (pt) | produtos terapêuticos para câncer de mama | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| NZ707773A (en) | Methods of treating liver diseases | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| IN2014DN03010A (enExample) | ||
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| GB2544385A (en) | Modulators of caspase-6 | |
| MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| GEP20196947B (en) | Bremelanotide therapy for female sexual dysfunction | |
| NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| RU2012110137A (ru) | Способ лечения инсулинорезистентности | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives | |
| PH12015500178A1 (en) | Injectable supersaturated acetaminophen solution for spinal administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted |